Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Viridian Therapeutics, Inc. (NASDAQ: VRDN). The investigation focuses on Viridian’s executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Viridian securities?
If you purchased Viridian securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471. There is no cost or obligation to you.
Background of the investigation
On March 30, 2026, Viridian announced topline results from its REVEAL-1 Phase 3 clinical trial. Among other things, the Company reported that the trial met its primary endpoint with high statistical significance. Viridian disclosed proptosis responder rates of approximately 54% for the every-four-week (Q4W) dosing cohort and approximately 63% for the every-eight-week (Q8W) dosing cohort, compared to approximately 18% for placebo at week 24.
In light of this disclosure, Johnson Fistel is investigating whether Viridian Therapeutics complied with the federal securities laws. If you suffered losses from your investment in Viridian stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com